

**Sujith Kalmadi, M.D.**

**Ironwood Cancer and Research Centers**

**Division of Oncology and Hematology**

Gastrointestinal Malignancies

**Education:**

**Doctor of Medicine, 1993**

Kastruba Medical College, Mangalore India

**Fellowship- Hematology & Medical Oncology, 2003-2006**

Cleveland Clinic, Cleveland, OH

**Residency in Medicine, 1995-1999**

Cleveland Clinic Foundation, Cleveland, OH

**Professional Experience:**

- 1/2019 – Present Chief Medical Officer, Ironwood Cancer & Research Centers, Chandler, AZ
- 6/2008 – Present Physician, Ironwood Cancer & Research Centers, Chandler, AZ
- 3/2011-Present Clinical Assistant Professor Midwestern University, Arizona College of Osteopathic Medicine, Glendale, Arizona.
- 11/2007 – 6/2008 Clinical Assistant Professor Baylor Medical College, Methodist Hospital / St. Luke's Hospital, Texas Oncology/ US Oncology, Houston, Texas.
- 06/2006-10/2007 Associate Staff Physician Solid tumor, hematologic oncology, and blood disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio
- 06/2003-06/2006 Fellow, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio
- 01/2002-06/2003 Chairman, Department of Medicine, Putnam Hospital, Palatka, Florida.
- 07/1999-06/2003 Staff Physician, Putnam Hospital, Palatka, Florida.

**Activities and Honors:**

Certifications:

American Board of Internal Medicine- Hematology

American Board of Internal Medicine- Oncology

American Board of Internal Medicine

### Awards, Honors and Committees:

PHOENIX Magazine Top Doctor Award

Clinical Instructor – Midwestern Medical School, Glendale, Arizona

Reviewer, American Board of Internal Medicine, Medical oncology subspecialty

Examination, 2007

Outstanding teacher of the year award, Hematology-Oncology fellowship program, Taussig cancer center, Cleveland Clinic, 2007

Reviewer, *Cancer*, 2005

Reviewer, *Journal of clinical oncology*, 2005

### **Professional Memberships:**

American Society of Hematology

American Society of Clinical Oncology

American College of Physicians

### **Publications:**

#### A. Journal publications:

- (1) Afatinib versus Erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-8): an open -label randomized controlled phase 3 trial. *Lancet oncology*, 2015 Aug; 16 (8): 897-907. Turner et al. Paloma Study group. Collaborator.
- (2) Palbociclib in hormone receptor positive advanced breast cancer. *New England Journal of Medicine*. 2015 Jul 16; 373 (3): 209-19. Soria Et al. Lux Lung 8 investigators. Collaborator.
- (3) Predictors of clinical outcomes of resected ampullary adenocarcinoma : a single institution experience. Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. *Eur J Surg Oncol* 2011 Sep; 37 (9)
- (4) Clinical Utility of temozolimide in the treatment of malignant paraganglioma: a preliminary report. Bravo EL, Kalmadi SR, Gill I. *Horm Metab Res*. 2009 Sep;41(9):703-6. Epub 2009 Jun 17.
- (5) Evolving perspectives of the role of novel agents in androgen independent prostate cancer.

Kalmadi S, Raghavan D. Indian J Urol 2008 Jul; 24 (3): 303-8

- (6) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the southwest oncology group (swog 9810). Kalmadi, S, Rankin, C, Kraut, M, Jacobs, A, Petrylak, D, Adelstein, D, Keohan, M, Taub, R and Borden, E. Lung Cancer 2008 May; 60 (2): 259-263.
- (7) Neoadjuvant Therapy for Hepatocellular Carcinoma: Is There an Optimal Approach? Almhanna, K, Kalmadi, S, Pelley, R, and Kim, R. Oncology; 2007 August; Volume 21, Number 9. Review.
- (8) Lenalidomide: the emerging role of a novel targeted agent in malignancies. Kalmadi, S., Baz, R., and Mahindra, A. Drugs Today (Barc). 2007 Feb;43(2):85-95. Review.
- (9) Epsilon Aminocaproic Acid reduces transfusion requirement in patients with thrombocytopenic hemorrhage. Kalmadi, S., Tiu, R., Lowe, C., and Kalaycio, M. Cancer: 2006; Volume 107; Issue 1; 136-40. Original article.
- (10) Phase I trial of three-weekly docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. Kalmadi, S., Davis, M., Dowlati, A., O'Keefe, S., Cline-Burkhardt, M., Pelley, R.J., Borden, E., Dreicer, R., Bukowski, R., and Mekhail, T. Investigational New drugs: 2006. Original article.
- (11) Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Kalmadi, S, Mc'Neill, G, Davis, M, Peereboom, D, Adelstein, D, Mekhail, T. Medical Oncology: 2006; Volume 23, No.3. Original article.
- (12) The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Kalmadi, S., and Hussein, M. Acta Haematologica; 2006; Vol. 116, 1-7. Review.
- (13) New biology of lung cancer: Prognostic factors and therapeutic impact: Kalmadi, S. Molecular Oncology Report, 2006. Review.
- (14) Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplants ever be discontinued. Gordon, S., LaRosa, S., Kalmadi, S., Arroliga, A., Avery, R., Truesdell-Larosa, L., and Longworth, D.L. Clinical Infectious diseases, 1999; 28 (2); 240-6. Original article.

**B. Books and/or Chapters:**

- (1) Uncommon tumors of the kidney in "Textbook of uncommon cancers- 3<sup>rd</sup> edition". Kalmadi, S., Zhou, M., Novick, A., and Bukowski, R. John Wiley and sons, 2005
- (2) Fundamentals of cancer treatment: Effects of chemotherapy on neoplastic cells in " Cancer in the spine: comprehensive care for spinal column tumors." Kalmadi, S., and Raghavan, D. Humana Press, 2005.

C. Abstracts:

- 1) Analysis of 140 cases with biliary tract cancer (BTC). K. Almhanna, R. Kim, S. Kalmadi, p. Elson, J. Dumot, M. Walsh, M. Henderson, R. J. Pelley. 2008 ASCO GI symposium.
- 2) Factors associated with tumor recurrence and 5-year postoperative survival in ampullary carcinoma: Cleveland Clinic Experience. A. Lazaryan, K. Almhanna, P. Elson, S. Kalmadi, D. Vogt, M. Walsh, M. Henderson, R. Pelley, R. Kim. 2008 ASCO GI symposium.
- 3) Is adjuvant radiation plus chemotherapy for resectable pancreatic adenocarcinoma associated with improved survival? The Cleveland Clinic experience. R. E. Tsao, K. Almhanna, A. Lazaryan, P. Elson, S. Kalmadi, R. J. Pelley, R. Kim, M. Walsh, M. J. Henderson, D. Vogt
- 4) Response to transarterial chemoembolization prior to liver transplantation or hepatic resection in patients with hepatocellular carcinoma. Almhanna, K, Golshayan, A, Sands, M, Levitin, A, Kim, R, Pelley, R, and Kalmadi, S. 2007 Annual ASCO meeting. Number 15114.
- 5) Nigro regimen treatment of squamous cell cancer of the anus. Kalmadi, S. Pelley, R, Kay, E, Saxton, J., Bukowski, R, Kim, R, Lavery, C and Fazio, V. 2007 Annual ASCO meeting. Number 14545.
- 6) Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. Kalmadi, S., Davis, M., Dowlati, A., O'Keefe, S., Cline-Burkhardt, M., Pelley, R.J., Borden, E., Dreicer, R., Bukowski, R., and Mekhail, T. 2006 annual ASCO meeting. Number 13027
- 7) Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer. McNeill, G., Kalmadi, S., Davis, M., Peereboom, D., Bukowski, R., and Mekhail, T. 2006 annual ASCO meeting. Number 17076.
- 8) Pilot study of SELDI-TOF in bone marrow failure syndromes. Kalmadi, S., Wu, R., Plasinova, M., Sloan, E., Galili, N., Raza, A., Maciejewski, J. 2005 ASCO annual meeting. Number 6547.

- 9) EACA is effective in controlling thrombocytopenic hemorrhage in patients with hematologic malignancies. Tiu, R., Kalmadi, S., Lowe, C., Sobecks, R., Bolwell, B., Lichtin, A., Kalaycio, M., Maciejewski, J., Advani, A., Sekeres, M., Pohlman, B. 2005 ASCO annual meeting. Number 6648
- 10) A pilot application of SELDI-TOF mass spectrometry in Bone marrow failure syndromes. Kalmadi, S., Wu, R., Nearman, Z., Elson, P., Sekeres, M., and Maciejewski, J. A American society of Hematology 2005 annual meeting. Number 3421.
- 11) Weekly docetaxel-gemcitabine as first line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study. Kalmadi, S., Mekhail, T., Adelstein, D., Giannini, C., Peereboom, D., Olencki, T., Davis, R, and Bukowski, R. 2004 ASCO annual meeting. Number 7236
- 12) EACA reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Kalmadi, S., Tiu, R., Lowe, C., Sobecks, R., Bolwell, B., Lichtin, A., Hussein, M., Maciejewski, J., Advani, A., Sekeres, M., Andresen, S., Pohlman, B., Elson, P., and Kalaycio, M. American society of hematology 2004 annual meeting. Number 3938.

D. Special Presentations :

- (1) " Methods in clinical cancer research." Workshop by American society of clinical oncology (ASCO) and American Association for Cancer Research. Vail, Colorado 2007.
- (2) "Utility of SELDI proteomics in hematologic disorders" at the advances in proteomics in cancer research. American Association of cancer Research (AACR). Poster presentation. Key Biscayne, Florida. October 2004.
- (3) "The changing epidemiology and outcome of neutropenic fever." Poster presentation. Resident research day, Cleveland Clinic Foundation, May 1999.
- (4) "Cystic diseases of the kidney, from childhood to adult life." Poster presentation. Department of Nephrology grand rounds, April 1998, Cleveland Clinic.

**Research Trials:**

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

**Other Activities:**

Hobbies etc.

